Early thrombocytopenia predicts longer time-to-treatment discontinuation in trastuzumab emtansine treatment

Basit Öğe Kaydı
dc.authoridŞahin, Ahmet Bilgehan/0000-0002-7846-0870
dc.authorwosidocakoglu, gokhan/AAH-5180-2021
dc.authorwosidOcak, Birol/AEC-2238-2022
dc.authorwosidŞahin, Ahmet Bilgehan/AAM-4927-2020
dc.contributor.authorSahin, Ahmet Bilgehan
dc.contributor.authorCaner, Burcu
dc.contributor.authorOcak, Birol
dc.contributor.authorGulmez, Ahmet
dc.contributor.authorHamitoglu, Buket
dc.contributor.authorCubukcu, Erdem
dc.contributor.authorDeligonul, Adem
dc.date.accessioned2024-08-04T20:54:52Z
dc.date.available2024-08-04T20:54:52Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThrombocytopenia is a characteristic adverse event of trastuzumab emtansine (T-DM1), one of the essential treatment options for human epithelial growth factor receptor 2 (HER2)-positive breast cancer. The present study investigated the predictive value of thrombocytopenia for time-to-treatment discontinuation (TTD) in patients receiving T-DM1 for advanced-stage HER2-positive breast cancer. The present observational study enrolled 138 patients who received T-DM1 at six oncology centers from January 2016 to December 2021. Univariate and multivariate Cox regression analyses were performed to determine the factors affecting TTD. The median age of patients was 50 years (range, 26-83). The median number of T-DM1 cycles was 9 (range, 2-58), the overall response rate was 50.0% and the disease control rate was 69.6%. At a median follow-up time of 19.3 months, the median TTD was 9.5 months [95% confidence interval (CI), 7.3-11.7], and the median overall survival was 28.2 months (95% CI, 19.2-37.2). Thrombocytopenia during treatment was observed in 39% of all patients, and 66.7% of these patients experienced early thrombocytopenia (in the first four treatment cycles). Multivariate analysis revealed that the independent factors for TTD were hormone receptor status [hazard ratio (HR), 1.837; 95% CI, 1.249-2.701; P=0.002], Eastern Cooperative Oncology Group performance status score (HR, 3.269; 95% CI, 1.788-5.976; P<0.001) and thrombocytopenia during treatment (HR, 0.297; 95% CI, 0.198-0.446; P<0.001). Patients with early thrombocytopenia had a significantly longer TTD of 17.3 months (95% CI, 11.8-22.8) compared with 7.6 months (95% CI, 5.8-9.4) for patients without early thrombocytopenia (P<0.001). The results of the present study indicated that patients with early thrombocytopenia had improved survival outcomes compared with those without. Thus, maximum benefit from T-DM1 treatment may be achieved by confirming the predictive role of thrombocytopenia in T-DM1 treatment in prospective studies and large-scale cohorts.en_US
dc.description.sponsorshipNot applicable.en_US
dc.description.sponsorshipNot applicable.en_US
dc.identifier.doi10.3892/ol.2023.14110
dc.identifier.issn1792-1074
dc.identifier.issn1792-1082
dc.identifier.issue6en_US
dc.identifier.pmid37927419en_US
dc.identifier.scopus2-s2.0-85178000757en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.3892/ol.2023.14110
dc.identifier.urihttps://hdl.handle.net/11616/101688
dc.identifier.volume26en_US
dc.identifier.wosWOS:001098750900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofOncology Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbreast canceren_US
dc.subjecttrastuzumab emtansineen_US
dc.subjectadverse eventen_US
dc.subjectthrombocytopeniaen_US
dc.subjectsurvivalen_US
dc.titleEarly thrombocytopenia predicts longer time-to-treatment discontinuation in trastuzumab emtansine treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu